Trial Profile

Phase II registrational trial of onapristone in patients with recurrent or metastatic endometrial cancer.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 23 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Onapristone (Primary)
Indications Endometrial cancer
Focus Registrational; Therapeutic Use
Sponsors Arno Therapeutics

Most Recent Events

16 May 2016 According to Arno Therapeutics media release, company closed this study. But the decision was not based on any safety or lack of efficacy signal and the Company will continue to provide onapristone to all patients currently enrolled in this trial on a compassionate use basis.
16 May 2016 Status changed from recruiting to discontinued, as per Arno Therapeutics media release.
30 Mar 2016 According to an Arno Therapeutics media release, status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com